Aetna Wun Trombley

Aetna Wun Trombley has served as an independent director of Carmot Therapeutics since 2016. She is currently the President and CEO and a director at Lycia Therapeutics, a private biotech company focused on discovering and developing potential first-in-class therapeutics that degrade extracellular proteins. Prior to joining Lycia, Dr. Trombley was President and Chief Operating Officer of NGM Biopharmaceuticals (NASDAQ: NGM), where she had broad strategic and operational responsibilities for nine years. At NGM, she was instrumental in establishing multiple strategic partnerships and a successful initial public offering in 2019. Previously, she served as Chief of Staff for the Chief Executive Officer of Novartis and worked at XenoPort (NASDAQ: XNPT) in business development. She started her career at McKinsey & Company, where she advised biopharmaceutical and medical device clients on strategic, commercial, and operational issues. She received a B.S. in Chemistry from the University of California, San Diego, and a Ph.D. in Chemistry from MIT.